kidney cancer

Guidelines update: Bladder, kidney, prostate cancerThis article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
Active surveillance: A potential role in metastatic RCC?Results from a recent prospective trial suggest that active surveillance may be suitable for some patients with advanced renal cell carcinoma.
Study data may help risk stratify microhematuria DxA recent study of patients with a new diagnosis of microhematuria finds that rates of bladder and kidney cancer as well as urolithiasis depend on how thoroughly the patients are evaluated.
Oral agent improves survival in advanced RCC patientsOnce-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.
Kidney Ca: Cytoreductive nephrectomy appears to be protectiveOther kidney cancer research included an 8-gene panel that was able to predict high tumor grade in biopsy specimens and a review of perioperative transfusion’s effect on recurrence-free and overall survival.
RCC: Two approvals expand options for TKI-refractory patientsFDA approval of second-line therapies could mean an “embarrassment of riches” in this field, according to one expert.
New treatment for kidney cancer gets OKFDA has approved lenvatinib (Lenvima, Eisai Inc.) in combination with everolimus for the treatment of advanced renal cell carcinoma.
AUA 2016: Experts offer guidance on the meetingTo guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.
Sunitinib vs. everolimus: PFS, toxicity differ in studyIn a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.
How renal mass biopsy impacts managementUrology Times SUO internship program member Robert M. Turner, II, MD, reports on a recent presentation by J. Stuart Wolf, Jr., MD, about possible pitfalls of renal mass biopsy.